Johnson & Johnson (JNJ) risk factors, FY2024 10-K

Risks related to our business, industry and operations

1. 01The Company’s businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company’s earnings
2. 02Interruptions and delays in manufacturing operations could adversely affect the Company’s business, sales and reputation
3. 03The Company relies on third parties to manufacture and supply certain of our products. Any failure by or loss of a third-party manufacturer or supplier could result in delays and increased costs, which may adversely affect our business
4. 04Counterfeit versions of our products could harm our patients and have a negative impact on our revenues, earnings, reputation and business
5. 05Global health crises, pandemics, epidemics, or other outbreaks could adversely disrupt or impact certain aspects of the Company’s business, results of operations and financial condition

Risks related to government regulation and legal proceedings

1. 06Global sales in the Company’s Innovative Medicine and MedTech segments may be negatively impacted by healthcare reforms and increasing pricing pressures
2. 07We are subject to an increasing number of costly and complex governmental regulations in the countries in which operations are conducted which may materially adversely affect the Company’s financial condition and business operations
3. 08The Company is subject to significant legal proceedings that can result in significant expenses, fines and reputational damage
4. 09Product reliability, safety and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational damage
5. 10The Company faces significant regulatory scrutiny, which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties
6. 11Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company’s operating results
7. 12See Note 8 Income taxes under Notes to the Consolidated Financial Statements included in Item 8 of this Report for additional information

Risks related to our intellectual property

1. 13The Company faces increased challenges to intellectual property rights central to its business

Risks related to product development, regulatory approval and commercialization

1. 14Significant challenges or delays in the Company’s innovation, development and implementation of new products, technologies and indications could have an adverse impact on the Company’s long-term success

Risks related to financial and economic market conditions

1. 15The Company’s extensive operations and business activity throughout the world are accompanied by certain financial, economic, legal, social and political risks, including those listed below
2. 16In addition, the impact of currency devaluations in countries experiencing high inflation rates or significant currency exchange fluctuations could negatively impact the Company’s operating results
3. 17Due to the international nature of the Company's business, geopolitical or economic changes or events, including global tensions and war, could adversely affect our business, results of operations or financial condition
4. 18Weak financial performance, failure to maintain a satisfactory credit rating or disruptions in the financial markets could adversely affect our liquidity, capital position, borrowing costs and access to capital markets

Other risks

1. 19Our business depends on our ability to recruit and retain talented and highly skilled employees
2. 20Climate change or legal, regulatory or market measures to address climate change may negatively affect our business and results of operations
3. 21An information security incident, including a cybersecurity breach, could have a negative impact on the Company’s business or reputation
4. 22A breach of privacy laws or unauthorized access, loss or misuse of personal data could have a negative impact on the Company’s business or reputation